Clinical Report: Severe Immune-Mediated Inflammatory Response Following Ivonescimab

Overview

This case study details a 72-year-old man with advanced EGFR-mutant lung squamous cell carcinoma who developed a severe IL-6-dominant inflammatory response and probable arginine vasopressin deficiency after treatment with ivonescimab. The findings highlight the potential for severe immune-related adverse events associated with this novel therapy.

Background

Ivonescimab is a PD-1/VEGF bispecific antibody that has shown efficacy in advanced lung cancer, yet the occurrence of severe immune-related adverse events (irAEs) remains underreported outside clinical trials. Understanding these irAEs is crucial, particularly as they can significantly impact patient management and outcomes in the context of immune checkpoint blockade.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

• A 72-year-old male with advanced EGFR-mutant lung squamous cell carcinoma developed persistent fever after ivonescimab treatment.
• Elevated IL-6 levels were observed, indicating an immune-mediated inflammatory response.
• Corticosteroids provided rapid relief from fever, suggesting an IL-6-mediated process.
• Re-exposure to ivonescimab resulted in a more severe reaction, including symptoms of arginine vasopressin deficiency.
• Early recognition and management of steroid-responsive fever and IL-6 monitoring are critical in such cases.

Clinical Implications

Clinicians should be vigilant for signs of severe immune-related adverse events, particularly in patients receiving ivonescimab. Monitoring IL-6 levels and considering corticosteroid treatment may be necessary for managing these reactions effectively.

Conclusion

This case underscores the potential for severe inflammatory responses and endocrine toxicity following ivonescimab treatment, necessitating careful monitoring and management strategies in susceptible patients.

Related Resources & Content

1. ASCO, Journal of Clinical Oncology, 2024 -- Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.1
2. IASLC -- Ivonescimab Outperforms Pembrolizumab in Phase 3 Study for First-Line Treatment of PD-L1-Positive Advanced NSCLC In HARMONi-2 Study
3. Frontiers in Immunology — Case Report: Long-term survival in advanced PD-L1-high squamous cell lung cancer following severe immune-related cardiotoxicity
4. Frontiers in Oncology — Sequential immune-related nephritis and pneumonitis during immune checkpoint inhibitor therapy: a case report
5. Blood Cancer Journal — Endothelial Activation and Stress Index Alongside Pre-lymphodepletion as Predictors of Outcomes in CAR-T Therapy for B-cell Lymphoma
6. Frontiers in Oncology — Glucocorticoids as adjunctive therapy for severe myelosuppression induced by combined immune checkpoint inhibitor and chemotherapy: a case report and literature review
7. Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in Sweden
8. Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.1 | Journal of Clinical Oncology
9. Ivonescimab Outperforms Pembrolizumab in Phase 3 Study for First-Line Treatment of PD-L1-Positive Advanced NSCLC In HARMONi-2 Study  | IASLC